Almirall stock holds focus after 2025 revenue and profit gains

Almirall stock (ES0157097017) is anchored by the companys 2025 annual results, which showed EUR 990.7 million in revenue, EUR 100.6 million in EBITDA and EUR 22.6 million in net profit. Revenue rose 10.0% at constant currency in 2025, while the EBITDA margin reached 30.3%, according to Almiralls investor relations materials.

Revenue up 10.0%

Almirall reported that 2025 sales reached EUR 990.7 million, with constant-currency growth of 10.0% and EBITDA of EUR 100.6 million. The margin expansion to 30.3% matters because it shows the group converting more of its top line into operating profit than in the prior period.

The same reporting set also put net profit at EUR 22.6 million for 2025, a clear step up from the loss-making years that often pressured sentiment around the Spanish dermatology group. That combination of revenue growth, profitability and margin improvement gives the stock a more visible earnings base.

Margin at 30.3%

For investors, the margin now matters most because it frames the next rerating debate more cleanly than the topline alone. A 30.3% EBITDA margin on EUR 990.7 million of revenue suggests the 2025 mix was efficient enough to leave room for further earnings leverage if growth holds.

That also gives context to the companys current narrative: the share story is less about one-off headlines and more about whether Almirall can keep compounding from a 2025 base that already delivered EUR 100.6 million in EBITDA and EUR 22.6 million in net income.

Product sales still matter

Almiralls dermatology franchise remains the commercial backdrop for those numbers, with product-level execution shaping the path from revenue to EBITDA. The 2025 figures show that the companys business mix is still defined by specialty dermatology rather than broad-market volume.

That makes the reported 10.0% constant-currency growth in 2025 especially relevant, because it indicates the group was able to grow while still lifting profitability. The key point is not just sales volume, but the conversion of those sales into a 30.3% EBITDA margin.

Stock level and valuation

A dated market quote was not available in the search material for this call, so the most current quantified reference point is the companys 2025 reported performance. In that setting, Almirall stock is best read through the lens of EUR 990.7 million in revenue, EUR 100.6 million in EBITDA and EUR 22.6 million in net profit.

Those figures provide a concrete baseline for the next reporting step, and they matter more than broad market language. The 2025 numbers are the freshest evidence in hand, and they show a business that entered the current period with better profitability than before.

Almirall stock is tied to a 2025 report set that combines EUR 990.7 million in revenue, EUR 100.6 million in EBITDA and EUR 22.6 million in net profit, with revenue up 10.0% at constant currency and an EBITDA margin of 30.3%.